Results 61 to 70 of about 249 (106)

<i>Trans</i>-inhibitory effect of dotinurad, a uricosuric agent on uric acid reabsorptive transporter URAT1

, 2022
Ikumi Tamai, Yoshiyuki Shirasaka, Fujita Kazuki, Hiroshi Arakawa, Qiunan Zhu   +4 more
core   +1 more source

Renal Nicotinate Handling by Urate Transporter 1: Hidden Benefits of Urate Transporter 1-Targetting Uricosuric Agents. [PDF]

Kidney360
Miyata H, Morimoto K, Hosoya T, Toyoda Y, Hosoyamada M, Takada T.   +5 more
europepmc   +1 more source

Urate transporters: Structural mechanisms and therapeutic opportunities in drug development. [PDF]

Acta Pharm Sin B
Yang Q, Xu S, Shi X, Pang J, Wu T, Zhan P.   +5 more
europepmc   +1 more source

A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad. [PDF]

Cardiol Res, 2023
Yanai H, Adachi H, Hakoshima M, Katsuyama H.   +3 more
europepmc   +1 more source

Changes in urinary albumin levels with dotinurad oral administration in hyperuricemic patients with microalbuminuria: a post hoc analysis. [PDF]

Clin Exp Nephrol
Takahashi T, Beppu T, Hosoya T, Yokota N.   +3 more
europepmc   +1 more source

高尿酸血症を呈する慢性腎臓病患者におけるドチヌラドとフェブキソスタットによる治療効果の比較

慢性腎臓病（CKD）患者は血清尿酸値が高いことが多く，高尿酸血症は腎不全や脳心血管病の危険因子となる．腎機能が低下している場合，高尿酸血症治療薬として尿酸排泄促進薬は効果的ではなく，尿酸生成抑制薬であるアロプリノール（ALP）も副作用に注意を要するが，フェブキソスタット（FBX）などの非プリン系キサンチンオキシダーゼ阻害薬が腎不全患者にも用いられるようになり，選択的尿酸再吸収阻害薬であるドチヌラド（DTN）も導入されている．本研究では ...
Tojo, Akihiro, Rai, Tatemitsu, Yokoyama, Shohei, 横山, 翔平, 石光, 俊彦, 高橋, 知里, 本多, 勇晴, 藤乘, 嗣泰, Takahashi, Chisato, Honda, Takeaki, Ishimitsu, Toshihiko, 賴, 建光   +11 more
core  

Firsekibart for steroid withdrawal in glucocorticoid-dependent refractory gout: a case report. [PDF]

Front Immunol
Tan J, Huang H, Tan L, Li B, She R, Long S.   +5 more
europepmc   +1 more source

The Long-Term Effects of the Selective Inhibitor of Urate Transporter 1, Dotinurad, on Metabolic Parameters and Renal Function in Japanese Patients With Asymptomatic Hyperuricemia. [PDF]

J Clin Med Res
Yanai H, Adachi H, Hakoshima M, Katsuyama H.   +3 more
europepmc   +1 more source

Hyperuricemia in Chronic Kidney Disease: Emerging Pathophysiology and a Novel Therapeutic Strategy. [PDF]

Int J Mol Sci
Takata T, Mae Y, Hoi S, Iyama T, Isomoto H.   +4 more
europepmc   +1 more source

New product intros (borofalan (10B) (first-in-class), dotinurad, lemborexant, osilodrostat, ozanimod, ripretinib, selumetinib sulfate, tirabrutinib hydrochloride, viltolarsen)

, 2020

core   +1 more source